

Enspryng

Patient Information:	
Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	
Prescriber Information:	
Name:	
NPI:	
Phone Number:	
Fax Number	
Address:	
City, State, Zip:	
Requested Medication	
Rx Name:	
Rx Strength	
Rx Quantity:	
Rx Frequency:	
Rx Route of	
Administration:	
Diagnosis and ICD Code:	
prescribed a medication for you quantities can be provided. Plea Upon receipt of the complete SECTION A: Please no requests. Pharmacy predications that are not prescribed as the control of the control of the complete predications that are not predicated as the provided as t	efit requires that we review certain requests for coverage with the prescriber. You have repatient that requires Prior Authorization before benefit coverage or coverage of additional asse complete the following questions then fax this form to the toll-free number listed below. In the form, prescription benefit coverage will be determined based on the plan's rules. The that supporting clinical documentation is required for ALL PA in ion authorization reviews can be subject to trial with additional of listed within the criteria. The policies are subject to change based ints, MDH transmittals and updates to treatment quidelines.
1 What is the diagno	sis or indication? ca Spectrum Disorder (NMOSD) (If checked, go to 2)
[] Other (If checked,	no further questions)
	medication be used in combination with ANY of the following: Yes No biosimilars, B) Soliris, C) Uplizna, D) Ocrevus, E) Actemra? [uestions.]

If you have any questions, call: 1-888-258-8250

Is the requested medication being prescribed by or in consultation with a neurologist? [If no, no further questions.] Is the patient currently receiving the requested medication? [If no, skip to question 10.] Has the patient been receiving medication samples for the requested medication? [If yes, skip to question 10.] Does the patient have a previously approved prior authorization (PA) on file with the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 9.] Has the patient been established on therapy for at least 3 months? [If no, skip to question 10.] Has documentation been submitted to confirm that the patient has had a clinical benefit from the use of the requested medication, according to the prescriber? [NOTE: Examples of clinical benefit include reduction in relapse rate, reduction in symptoms (such as, pain, fatigue, motor function), and a slowing in progression of symptoms.] [No further questions.] Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] Is the patient greater than or equal to 18 years of age? [If no, no further questions.] Is the patient have a documented diagnosis of neuromyelitis optica spectrum disorder? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] Action REQUIRED: Submit supporting documentation. [If no, no further questions.] Does the patient have a documented to confirm a positive blood serum test for antiaquaporin-4 antibody? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]				
[If no, skip to question 10.] Has the patient been receiving medication samples for the requested medication? Yes No [If yes, skip to question 10.] Does the patient have a previously approved prior authorization (PA) on file with the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 9.] Has the patient been established on therapy for at least 3 months? Yes No [If no, skip to question 10.] Has documentation been submitted to confirm that the patient has had a clinical benefit from the use of the requested medication, according to the prescriber? [NOTE: Examples of clinical benefit include reduction in relapse rate, reduction in symptoms (such as, pain, fatigue, motor function), and a slowing in progression of symptoms.] [No further questions.] Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] Is the patient greater than or equal to 18 years of age? Yes No [If no, no further questions.] Does the patient have a documented diagnosis of neuromyelitis optica spectrum disorder? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] Has documentation been submitted to confirm a positive blood serum test for antiaquaporin-4 antibody? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] Does the patient have a documented for the following core clinical characteristics of Neuromyelitis Optica Spectrum Disorder (NMOSD): A) Optic neuritis, B) Acute myelitis, C) Area postrema syndrome, D) Acute brainstem syndrome, E) Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions, F) Symptomatic cerebral syndrome with	3	neurologist?	Yes	No
[If yes, skip to question 10.] Does the patient have a previously approved prior authorization (PA) on file with the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 9.] Has the patient been established on therapy for at least 3 months? [If no, skip to question 10.] Has documentation been submitted to confirm that the patient has had a clinical benefit from the use of the requested medication, according to the prescriber? [NOTE: Examples of clinical benefit include reduction in relapse rate, reduction in symptoms (such as, pain, fatigue, motor function), and a slowing in progression of symptoms.] [No further questions.] Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] 10 Is the patient greater than or equal to 18 years of age? [If no, no further questions.] 11 Does the patient have a documented diagnosis of neuromyelitis optica spectrum disorder? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] 12 Has documentation been submitted to confirm a positive blood serum test for antiaquaporin-4 antibody? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] 13 Does the patient exhibit at least ONE of the following core clinical characteristics of Neuromyelitis Optica Spectrum Disorder (NMOSD): A) Optic neuritis, B) Acute myelitis, C) Area postrema syndrome, D) Acute brainstem syndrome, E) Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions, F) Symptomatic cerebral syndrome with	4	·	Yes	No
the current plan? [Note: if the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 9.] 7 Has the patient been established on therapy for at least 3 months? [If no, skip to question 10.] 8 Has documentation been submitted to confirm that the patient has had a clinical benefit from the use of the requested medication, according to the prescriber? [NOTE: Examples of clinical benefit include reduction in relapse rate, reduction in symptoms (such as, pain, fatigue, motor function), and a slowing in progression of symptoms.] [No further questions.] 9 Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] 10 Is the patient greater than or equal to 18 years of age? [If no, no further questions.] 11 Does the patient have a documented diagnosis of neuromyelitis optica spectrum disorder? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] 12 Has documentation been submitted to confirm a positive blood serum test for antiaquaporin-4 antibody? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] 13 Does the patient exhibit at least ONE of the following core clinical characteristics of Neuromyelitis Optica Spectrum Disorder (NMOSD): A) Optic neuritis, B) Acute myelitis, C) Area postrema syndrome, D) Acute brainstem syndrome with NMOSD-typical diencephalic MRI lesions, F) Symptomatic cerebral syndrome with	5		Yes	No
[If no, skip to question 10.] 8	6	the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.]	Yes	No
benefit from the use of the requested medication, according to the prescriber? [NOTE: Examples of clinical benefit include reduction in relapse rate, reduction in symptoms (such as, pain, fatigue, motor function), and a slowing in progression of symptoms.] [No further questions.] 9 Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] 10 Is the patient greater than or equal to 18 years of age? [If no, no further questions.] 11 Does the patient have a documented diagnosis of neuromyelitis optica spectrum disorder? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] 12 Has documentation been submitted to confirm a positive blood serum test for antiaquaporin-4 antibody? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] 13 Does the patient exhibit at least ONE of the following core clinical characteristics of Neuromyelitis Optica Spectrum Disorder (NMOSD): A) Optic neuritis, B) Acute myelitis, C) Area postrema syndrome, D) Acute brainstem syndrome, E) Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions, F) Symptomatic cerebral syndrome with	7		Yes	No
clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] 10 Is the patient greater than or equal to 18 years of age? [If no, no further questions.] 11 Does the patient have a documented diagnosis of neuromyelitis optica spectrum disorder? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] 12 Has documentation been submitted to confirm a positive blood serum test for antiaquaporin-4 antibody? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] 13 Does the patient exhibit at least ONE of the following core clinical characteristics of Neuromyelitis Optica Spectrum Disorder (NMOSD): A) Optic neuritis, B) Acute myelitis, C) Area postrema syndrome, D) Acute brainstem syndrome, E) Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions, F) Symptomatic cerebral syndrome with	8	benefit from the use of the requested medication, according to the prescriber? [NOTE: Examples of clinical benefit include reduction in relapse rate, reduction in symptoms (such as, pain, fatigue, motor function), and a slowing in progression of symptoms.]	Yes	No
 [If no, no further questions.] Does the patient have a documented diagnosis of neuromyelitis optica spectrum disorder? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] Has documentation been submitted to confirm a positive blood serum test for antiaquaporin-4 antibody? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] Does the patient exhibit at least ONE of the following core clinical characteristics of Neuromyelitis Optica Spectrum Disorder (NMOSD): A) Optic neuritis, B) Acute myelitis, C) Area postrema syndrome, D) Acute brainstem syndrome, E) Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions, F) Symptomatic cerebral syndrome with 	9	clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation.	Yes	No
disorder? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] Has documentation been submitted to confirm a positive blood serum test for antiaquaporin-4 antibody? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] Does the patient exhibit at least ONE of the following core clinical characteristics of Neuromyelitis Optica Spectrum Disorder (NMOSD): A) Optic neuritis, B) Acute myelitis, C) Area postrema syndrome, D) Acute brainstem syndrome, E) Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions, F) Symptomatic cerebral syndrome with	10		Yes	No
 aquaporin-4 antibody? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] Does the patient exhibit at least ONE of the following core clinical characteristics Yes No of Neuromyelitis Optica Spectrum Disorder (NMOSD): A) Optic neuritis, B) Acute myelitis, C) Area postrema syndrome, D) Acute brainstem syndrome, E) Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions, F) Symptomatic cerebral syndrome with 	11	disorder? ACTION REQUIRED: Submit supporting documentation.	Yes	No
of Neuromyelitis Optica Spectrum Disorder (NMOSD): A) Optic neuritis, B) Acute myelitis, C) Area postrema syndrome, D) Acute brainstem syndrome, E) Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions, F) Symptomatic cerebral syndrome with	12	aquaporin-4 antibody? ACTION REQUIRED: Submit supporting documentation.	Yes	No
	13	of Neuromyelitis Optica Spectrum Disorder (NMOSD): A) Optic neuritis, B) Acute myelitis, C) Area postrema syndrome, D) Acute brainstem syndrome, E) Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions, F) Symptomatic cerebral syndrome with	Yes	No

If you have any questions, call: 1-888-258-8250

	NMOSD-typical brain lesions? [If no, no further questions.]		
14	Does the patient have an Expanded Disability Status Score (EDSS) of less than or equal to 6.5? [If no, no further questions.]	Yes	No
15	Has documentation been submitted to confirm that the patient has an intolerance to, contraindication to, or trial and failure with Soliris? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
16	Has documentation been submitted to confirm that the patient has an intolerance to, contraindication to, or trial and failure with rituximab? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
17	Has documentation been submitted to confirm that the patient has a history of at least one relapse in the last 12 months or two relapses in the last 2 years? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
18	Has documentation been submitted to confirm that the patient has a negative hepatitis B virus (HBV) test prior to treatment with the requested medication? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
19	Has the patient been screened for liver transaminases and latent tuberculosis (TB) prior to treatment and will continue to be monitored throughout therapy? [If no, no further questions.]	Yes	No
20	Has documentation been submitted to confirm that the patient is currently receiving or has previously had a trial and failure of at least TWO of the following systemic therapies: A) Azathioprine, B) Corticosteroid (such as prednisone, methylprednisolone) C) mycophenolate mofetil? ACTION REQUIRED: Submit supporting documentation.	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:



SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 1-888-258-8250

Version 07.2025